Pharmacology of Dostarlimab: A Review
Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological ch...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Krupanidhi College of Pharmacy
2022-09-01
|
| Series: | Journal of Pharmaceutical Research |
| Online Access: | https://jopcr.com/articles/pharmacology-of-dostarlimab-a-review |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Dostarlimab is a humanised anti-PD-1 immunoglobulin (IgG4) monoclonal antibody (mAb). It has a high affinity for the PD-1 receptor and effectively inhibits interactions with PD-L1 and PD-L2 by blocking their binding to the PD-1 receptor. Programmed cell death 1 (PD-1) is an immunological checkpoint receptor that transmits inhibitory signals to limit local inflammatory responses and preserve self-tolerance. It is found on antigen-activated and fatigued T cells. When the PD-1 receptor binds to the tumor-expressed ligands PD-L1 and PD-L2, T-cell proliferation and cytokine production are suppressed. Keywords: Dostarlimab, PD1 immunoglobulin, T - cell proliferation |
|---|---|
| ISSN: | 0973-7200 2454-8405 |